# Immunological and molecular insights into acinar-ductal metaplasia and atypical flat lesions as precursor lesions of pancreatic ductal adenocarcinoma

**Authors:** Aslihan Yavas, Leon Boshoven, Kai Horny, Sebastian Haensch, Wolfgang Goering, Martin Schlensog, Lena Haeberle, Irene Esposito

PMC · DOI: 10.1186/s13046-026-03643-4 · Journal of Experimental & Clinical Cancer Research : CR · 2026-01-13

## TL;DR

This study explores how certain pancreatic lesions may develop into cancer by analyzing their immune and genetic features.

## Contribution

The study identifies unique immunological and genetic characteristics of atypical flat lesions as potential precursors to pancreatic cancer.

## Key findings

- Atypical flat lesions show higher infiltration of immune cells compared to other precursor lesions.
- Genetic alterations in preneoplastic lesions include frequent mutations in Arid1a, Rnf43, and Pik3ca.
- PDAC in fKPC mice shows higher CXCL12 expression and CD109+ cells compared to other lesions.

## Abstract

Pancreatic ductal adenocarcinoma (PDAC) is known to develop through a stepwise progression from precursor lesions, such as pancreatic intraepithelial neoplasias (PanIN). An alternative carcinogenic pathway has been proposed via transformation of acinar cells, with development of acinar-ductal metaplasia (ADM) and atypical flat lesions (AFL). Defining the characteristics of PDAC precursors is crucial to better understand PDAC carcinogenesis.

15 KC (Ptf1aCre/+, KrasLSLG12D/+) and 15 KPC-like mice (Ptf1aCre/+, KrasLSLG12D/+, Trp53LoxP/LoxP, referred as fKPC hereafter) were sacrificed at different time points. A meticulous morphological evaluation was performed to define different lesion types. Multiplex immunofluorescence staining was applied to define the characteristics of the immune and stromal microenvironment of the lesions. To investigate the association between the genetic alterations and the components of the microenvironment, all lesion types were subjected to next-generation sequencing (NGS) using a 20 genes-panel.

AFL showed a trend towards a more intense immune cell infiltration compared to PanIN and ADM. AFL had higher number of CD4+ helper T cells, FOXP3+ regulatory T cells, and CD19+ B cells than all other analyzed lesions. They displayed more CD8+ cytotoxic T cells and FOXP3+ cells than PDAC, while peripheral and central PDAC tissues tended to be infiltrated by macrophages in higher frequency. In addition, αSMA-expressing myofibroblastic cancer-associated fibroblasts were tendentially more frequent in AFL than other lesions. PDAC appeared to have higher CXCL12 expression and more common CD109+ cells than other lesions. In NGS analysis, none of the lesions in fKPC mice revealed additional coding mutations, while the preneoplastic lesions in 7 KC mice showed variable coding alterations in 16 different genes. The most frequently affected genes were Arid1a, Rnf43, and Pik3ca. PDAC precursors in KC mice showed more dense infiltration of adaptive immune cells than in fKPC mice, supporting the immunosuppressive role of Trp53 alterations.

Our study highlights the unique immunological and stromal features of AFL. Moreover, reinforcing their potential as precursor lesions, ADM and AFL exhibit variable alterations in the genes that have a critical role in PDAC carcinogenesis.

The online version contains supplementary material available at 10.1186/s13046-026-03643-4.

## Linked entities

- **Genes:** PTF1A (pancreas associated transcription factor 1a) [NCBI Gene 256297], KRAS (KRAS proto-oncogene, GTPase) [NCBI Gene 3845], TP53 (tumor protein p53) [NCBI Gene 7157], ARID1A (AT-rich interaction domain 1A) [NCBI Gene 8289], RNF43 (ring finger protein 43) [NCBI Gene 54894], PIK3CA (phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha) [NCBI Gene 5290], CXCL12 (C-X-C motif chemokine ligand 12) [NCBI Gene 6387], CD109 (CD109 molecule) [NCBI Gene 135228], CD4 (CD4 molecule) [NCBI Gene 920], FOXP3 (forkhead box P3) [NCBI Gene 50943], CD19 (CD19 molecule) [NCBI Gene 930], CD8A (CD8 subunit alpha) [NCBI Gene 925], ACTA1 (actin alpha 1, skeletal muscle) [NCBI Gene 58]
- **Diseases:** pancreatic ductal adenocarcinoma (MONDO:0005184)
- **Species:** Mus musculus (taxon 10090)

## Full-text entities

- **Genes:** Ms4a1 (membrane-spanning 4-domains, subfamily A, member 1) [NCBI Gene 12482] {aka Cd20, Ly-44, Ms4a2}, Pik3ca (phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha) [NCBI Gene 18706] {aka 6330412C24Rik, caPI3K, p110, p110alpha}, Pten (phosphatase and tensin homolog) [NCBI Gene 19211] {aka 2310035O07Rik, A130070J02Rik, B430203M17Rik, MMAC1, PTENbeta, TEP1}, Ctnnb1 (catenin beta 1) [NCBI Gene 12387] {aka Bfc, Catnb, Mesc}, Tgfbr2 (transforming growth factor, beta receptor II) [NCBI Gene 21813] {aka 1110020H15Rik, DNIIR, RIIDN, TBR-II, TbetaR-II, TbetaRII}, Cxcl12 (C-X-C motif chemokine ligand 12) [NCBI Gene 20315] {aka Pbsf, Scyb12, Sdf1, Tlsf, Tpar1}, Smad4 (SMAD family member 4) [NCBI Gene 17128] {aka D18Wsu70e, DPC4, Madh4}, Cd109 (CD109 antigen) [NCBI Gene 235505] {aka 9930012E15Rik, GARP}, Arid1a (AT-rich interaction domain 1A) [NCBI Gene 93760] {aka 1110030E03Rik, BAF250, BAF250a, Osa1, Smarcf1}, Idh1 (isocitrate dehydrogenase 1 (NADP+), soluble) [NCBI Gene 15926] {aka E030024J03Rik, Id-1, Idh-1, Idpc}, ACTA1 (actin alpha 1, skeletal muscle) [NCBI Gene 58] {aka ACTA, ASMA, CFTD, CFTD1, CFTDM, CMYO2A}, Cd63 (CD63 antigen) [NCBI Gene 12512] {aka ME491, Tspan30}, Cd19 (CD19 antigen) [NCBI Gene 12478], Acta2 (actin alpha 2, smooth muscle, aorta) [NCBI Gene 11475] {aka 0610041G09Rik, Actvs, SMAalpha, SMalphaA, a-SMA, alphaSMA}, KRT19 (keratin 19) [NCBI Gene 3880] {aka CK19, K19, K1CS}, Iars1 (isoleucyl-tRNA synthetase 1) [NCBI Gene 105148] {aka 2510016L12Rik, E430001P04Rik, ILRS, Iars}, Alk (anaplastic lymphoma kinase) [NCBI Gene 11682] {aka CD246, Tcrz}, Foxp3 (forkhead box P3) [NCBI Gene 20371] {aka JM2, scurfin, sf}, Cdkn2a (cyclin dependent kinase inhibitor 2A) [NCBI Gene 12578] {aka ARF-INK4a, Arf, INK4a-ARF, Ink4a/Arf, MTS1, Pctr1}, Cd4 (CD4 antigen) [NCBI Gene 12504] {aka L3T4, Ly-4}, Trp53 (transformation related protein 53) [NCBI Gene 22059] {aka Tp53, bbl, bfy, bhy, p44, p53}, Gnas (GNAS complex locus) [NCBI Gene 14683] {aka 5530400H20Rik, A930027G11Rik, C130027O20Rik, GPSA, GSP, Galphas}, Braf (B-Raf proto-oncogene, serine/threonine kinase) [NCBI Gene 109880] {aka 9930012E13Rik, B-raf, Braf-2, Braf2, C230098H17, D6Ertd631e}, Kras (Kras proto-oncogene, GTPase) [NCBI Gene 16653] {aka K-Ras, K-Ras 2, K-ras, Ki-ras, Kras-2, Kras2}, Egfr (epidermal growth factor receptor) [NCBI Gene 13649] {aka 9030024J15Rik, Erbb, Errb1, Errp, Wa5, wa-2}, Rnf43 (ring finger protein 43) [NCBI Gene 207742] {aka 4732452J19Rik}, Adm (adrenomedullin) [NCBI Gene 11535] {aka AM}, Stk11 (serine/threonine kinase 11) [NCBI Gene 20869] {aka Lkb1, Par-4}, Ptf1a (pancreas specific transcription factor, 1a) [NCBI Gene 19213] {aka PTF1-p48, PTF1p48, bHLHa29}, Apc (APC, WNT signaling pathway regulator) [NCBI Gene 11789] {aka CC1, Min, mAPC}, Nras (Nras proto-oncogene, GTPase) [NCBI Gene 18176] {aka N-ras}, Cxcr4 (C-X-C motif chemokine receptor 4) [NCBI Gene 12767] {aka CD184, CXC-R4, CXCR-4, Cmkar4, LESTR, PB-CKR}, Fgfr2 (fibroblast growth factor receptor 2) [NCBI Gene 14183] {aka Bek, Fgfr-2, Fgfr-7, Fgfr2b, Fgfr7, KGFR}, Fbxw7 (F-box and WD-40 domain protein 7) [NCBI Gene 50754] {aka 1110001A17Rik, AGO, Cdc4, Fbw7, Fbwd6, Fbx30}, Adgre1 (adhesion G protein-coupled receptor E1) [NCBI Gene 13733] {aka DD7A5-7, EGF-TM7, Emr1, F4/80, Gpf480, Ly71}, Idh2 (isocitrate dehydrogenase 2 (NADP+), mitochondrial) [NCBI Gene 269951] {aka E430004F23, IDPm, Idh-2}
- **Diseases:** AFL (MESH:D005413), tumorigenic (MESH:D002471), fibrosis (MESH:D005355), Myofibroblastic cancer (MESH:D009369), mucinous (MESH:D002288), dysplasia (MESH:D015792), carcinogenic (MESH:D011230), pancreatic cancer (MESH:D010190), pancreatic lesions (MESH:D010182), PanIN (MESH:D002578), PDAC (MESH:D021441), carcinogenesis (MESH:D063646), chronic inflammation (MESH:D007249), MCN (MESH:D018297), acute pancreatic injury (MESH:D010195), IPMN (MESH:D000077779), metastases (MESH:D009362), chronic pancreatitis (MESH:D050500)
- **Chemicals:** Varlociraptor (-), Formalin (MESH:D005557), DAPI (MESH:C007293), Hematoxylin (MESH:D006416), paraffin (MESH:D010232), Eosin (MESH:D004801)
- **Species:** Homo sapiens (human, species) [taxon 9606], Legionella sp. H (species) [taxon 66966], Mus musculus (house mouse, species) [taxon 10090]
- **Cell lines:** AFL — Homo sapiens (Human), Prader-Willi syndrome, Induced pluripotent stem cell (CVCL_ZJ55), PanIN — Mesocricetus auratus (Golden hamster), Hamster pancreatic ductal adenocarcinoma, Cancer cell line (CVCL_5M15), cPDAC — Homo sapiens (Human), Pancreatic ductal adenocarcinoma, Cancer cell line (CVCL_B7A6)

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12849142/full.md

## Figures

9 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12849142/full.md

## References

6 references — full list in the complete paper: https://tomesphere.com/paper/PMC12849142/full.md

---
Source: https://tomesphere.com/paper/PMC12849142